Gefitinib sensitivity-related gene expression and products and methods related thereto

US8017321B2 · kind B2 · utility

Assignee

• The Regents of the University of Colorado, a Body Corporate · US

Inventors

• Paul Bunn · Evergreen, US
• Christopher D. COLDREN · Denver, US
• Wilbur Franklin · Richmond, US
• Mark W. Geraci · Aurora, US
• Barbara A. HELFRICH · Lakewood, US
• Fred R. Hirsch · Denver, US
• Razvan Lapadat · Denver, US
• Michio Sugita · Centennial, US
• Samir E. Witta · Greenwood Village, US

Key dates

• Filing date: Jan 24, 2005
• Grant date: Sep 13, 2011
• Expiry date: Jan 24, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/136
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.